UPDATE | June 12, 2023

Leveraging CLD technology to overcome associated challenges

  • MAIL

Leveraging CLD technology to overcome associated challenges

High-titer biologics production with maximized productivity and quality is crucial for efficient biomanufacturing. In this article for the Innovations in Pharmaceutical Technology magazine, Yingji Jin, a Lead Scientist in our Cell Line Development Group, discusses how Samsung Biologics' CLD platform with high-titer capabilities can help streamline biologics manufacturing to deliver essential treatments to patients faster.

Read more

Leveraging CLD technology to overcome associated challenges

High-titer biologics production with maximized productivity and quality is crucial for efficient biomanufacturing. In this article for the Innovations in Pharmaceutical Technology magazine, Yingji Jin, a Lead Scientist in our Cell Line Development Group, discusses how Samsung Biologics' CLD platform with high-titer capabilities can help streamline biologics manufacturing to deliver essential treatments to patients faster.

Read more 

  • CDO
  • CGMP
  • ADC
  • Bio Campus
  • IR
  • CMO

Share article

  • MAIL

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required